Provider-, Site-Level Factors Linked to Testosterone Receipt

Share this content:
Provider-, Site-Level Factors Linked to Testosterone Receipt
Provider-, Site-Level Factors Linked to Testosterone Receipt

MONDAY, July 24, 2017 (HealthDay News) -- Provider- and site-level factors, including experience, specialty, and site location, are associated with testosterone prescribing, according to a study published online July 18 in the Journal of Clinical Endocrinology and Metabolism.

Guneet K. Jasuja, Ph.D., from the Center for Healthcare Organization and Implementation Research in Bedford, Mass., and colleagues conducted a cross-sectional study to examine provider- and site-level determinants of testosterone receipt in a national cohort of male patients. Participants received at least one outpatient prescription within the Veterans Health Administration (VA); 38,659 providers and 130 stations were associated with the patients.

The researchers found that the likelihood of prescribing testosterone was increased for providers ranging in age from 31 to 60 years, with less experience in the VA (all adjusted odds ratios (aORs), <2.0), and credentialed as physicians in endocrinology and urology (aORs, 3.86 and 1.50, respectively), compared with older providers, providers of longer VA tenure, and primary care providers, respectively. Testosterone use was also more likely at sites located in the West versus the Northeast (aOR, 1.75) and for care received at a community-based outpatient clinic versus a medical center (aOR, 1.22). Compared with primary care providers, endocrinologists were also more likely to obtain an appropriate work-up before prescribing (aOR, 2.14).

"Our results highlight the opportunity to intervene both at the provider and the site level to improve testosterone prescribing," the authors write. "Beyond testosterone, this study provides a useful example of how to examine contributions to prescribing variation at different levels of the health care system."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Zika Does Not Appear to Last in Semen As Long As Thought

Zika Does Not Appear to Last in Semen ...

More research is needed to better inform public health recommendations

Radioiodine Therapy for Thyroid Cancer Doesn't Up Stroke Risk

Radioiodine Therapy for Thyroid Cancer Doesn't Up Stroke ...

I-131 therapy group showed no significantly higher risk of ischemic or hemorrhagic stroke

Higher Odds of Infection With Reduced Kidney Function

Higher Odds of Infection With Reduced Kidney Function

Study finds excess community-acquired infections incidence in individuals with mild to severe CKD

is free, fast, and customized just for you!

Already a member?

Sign In Now »